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Background
Preclinical and some clinical studies suggest a relationship
between perturbation in magnesium homeostasis and
pathological anxiety, although the underlying mechanisms
remain largely unknown. Since there is evidence that
Mg
2+ modulates the hypothalamic-pituitary-adrenal
(HPA) axis, we tested whether enhanced anxiety-like beha-
viour can be reliably elicited by dietary Mg
2+ restriction
and whether Mg
2+ deficiency is associated with altered
HPA axis function.
Methods
Mice assigned to Mg
2+-deficient groups were allowed to
freely access a 0.005% Mg
2+-containing diet while control
mice were fed a normal, 0.2% Mg
2+-containing diet. The
emotional behaviour of Mg
2+-deficient mice was assessed
in a battery of anxiety tests including the open field test,
the light/dark test, the stress-induced hypothermia test,
and the hyponeophagia test. Markers of HPA axis func-
tion including CRH gene expression and plasma ACTH
levels were quantified. Neuronal activation patterns in
the HPA system were investigated using mapping of the
immediate early gene c-Fos as a marker of neuronal acti-
vation in response to an anxiety-provoking situation.
Results
Compared to controls, Mg
2+-deficient mice did indeed
display enhanced anxiety-related behaviour in numerous
anxiety tests. The enhanced anxiety-related behaviour of
Mg
2+-deficient mice was sensitive to chronic desipra-
mine treatment in the hyponeophagia test and to acute
diazepam treatment in the open arm exposure test.
Mg
2+ deficiency caused an increase in the transcription
of corticotropin releasing hormone in the paraventricu-
lar hypothalamic nucleus (PVN), which coincided with
elevated ACTH plasma levels, pointing to an enhanced
set-point of the HPA axis. Chronic treatment with desi-
pramine reversed the identified abnormalities of the
stress axis. Functional mapping of neuronal activity
revealed hyper-excitability in the PVN of anxious Mg
2+-
deficient mice and its normalisation through diazepam
treatment.
Conclusions
Overall, the present findings demonstrate the robustness
and validity of the Mg
2+ deficiency model as a mouse
model of enhanced anxiety, showing sensitivity to treat-
ment with anxiolytics and antidepressants. It is further
suggested that dysregulations in the HPA axis may con-
tribute to the hyper-emotionality in response to dietary
induced hypomagnesaemia.
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